Donald M. Jensen

Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

Stefan Zeuzem, Ira M. Jacobson, Tolga Baykal et al. · New England Journal of Medicine · 2014 · 519 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon α-2a (40 kd)/ribavirin therapy

Donald M. Jensen, Timothy R. Morgan, Patrick Marcellin et al. · Hepatology · 2006 · 470 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Efficacy and Safety of Pegylated (40–Kd) Interferon α–2A Compared With Interferon α–2A in Noncirrhotic Patients With Chronic Hepatitis C

K. Rajender Reddy, Teresa L. Wright, Paul J. Pockros et al. · Hepatology · 2001 · 360 citations

Pharmacy, Pharmacokinetics, Pharmacology +17

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

Eric Lawitz, Jay Lalezari, Tarek Hassanein et al. · The Lancet Infectious Diseases · 2013 · 328 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Predictive value of <scp>ALT</scp> levels for non‐alcoholic steatohepatitis (<scp>NASH</scp>) and advanced fibrosis in non‐alcoholic fatty liver disease (<scp>NAFLD</scp>)

Siddharth Verma, Donald M. Jensen, John Hart et al. · Liver International · 2013 · 320 citations

Medicine, Internal Medicine, Pathology +17